CA3235356A1 - Novel methods - Google Patents
Novel methods Download PDFInfo
- Publication number
- CA3235356A1 CA3235356A1 CA3235356A CA3235356A CA3235356A1 CA 3235356 A1 CA3235356 A1 CA 3235356A1 CA 3235356 A CA3235356 A CA 3235356A CA 3235356 A CA3235356 A CA 3235356A CA 3235356 A1 CA3235356 A1 CA 3235356A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- fentanyl
- opioid
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163262732P | 2021-10-19 | 2021-10-19 | |
| US63/262,732 | 2021-10-19 | ||
| PCT/US2022/078177 WO2023069880A1 (en) | 2021-10-19 | 2022-10-14 | Novel methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3235356A1 true CA3235356A1 (en) | 2023-04-27 |
Family
ID=86058575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3235356A Pending CA3235356A1 (en) | 2021-10-19 | 2022-10-14 | Novel methods |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240415832A1 (https=) |
| EP (1) | EP4419523A4 (https=) |
| JP (1) | JP2024539106A (https=) |
| KR (1) | KR20240089771A (https=) |
| CN (1) | CN118556058A (https=) |
| AU (1) | AU2022368858A1 (https=) |
| CA (1) | CA3235356A1 (https=) |
| IL (1) | IL312165A (https=) |
| MX (1) | MX2024004725A (https=) |
| WO (1) | WO2023069880A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3898580A4 (en) | 2018-12-17 | 2022-08-10 | Intra-Cellular Therapies, Inc. | SYNTHESIS OF CONDENSED GAMMA-CARBOLINES WITH SUBSTITUTED HETEROCYCLE |
| IL283963B2 (en) | 2018-12-17 | 2025-01-01 | Intra Cellular Therapies Inc | Synthesis of condensed gamma-carbolines and converted heterocycles |
| WO2020132605A1 (en) | 2018-12-21 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2024194263A1 (en) | 2023-03-17 | 2024-09-26 | Norwegian University Of Life Sciences | Serotonin 5ht2a receptor antagonist for use in treating side effects resulting form mu opioid receptor agonist overdose |
| WO2026011136A1 (en) * | 2024-07-03 | 2026-01-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2026011166A1 (en) * | 2024-07-03 | 2026-01-08 | Intra-Cellular Therapies, Inc. | Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7223742B2 (ja) * | 2017-07-26 | 2023-02-16 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| US20220160704A2 (en) * | 2018-08-08 | 2022-05-26 | Torralva Medical Therapeutics Llc | Compositions for opiate and opioid prevention and reversal, and methods of their use |
| WO2020132605A1 (en) * | 2018-12-21 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN118105390A (zh) * | 2019-01-23 | 2024-05-31 | 细胞内治疗公司 | 治疗成瘾的方法 |
| CA3139168A1 (en) * | 2019-05-07 | 2020-11-12 | Nirsum Laboratories, Inc. | Opioid receptor antagonist prodrugs |
| EP4493560A4 (en) * | 2022-03-14 | 2026-03-18 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS |
-
2022
- 2022-10-14 MX MX2024004725A patent/MX2024004725A/es unknown
- 2022-10-14 KR KR1020247016018A patent/KR20240089771A/ko active Pending
- 2022-10-14 US US18/703,145 patent/US20240415832A1/en active Pending
- 2022-10-14 IL IL312165A patent/IL312165A/en unknown
- 2022-10-14 JP JP2024523484A patent/JP2024539106A/ja active Pending
- 2022-10-14 EP EP22884603.6A patent/EP4419523A4/en active Pending
- 2022-10-14 CA CA3235356A patent/CA3235356A1/en active Pending
- 2022-10-14 WO PCT/US2022/078177 patent/WO2023069880A1/en not_active Ceased
- 2022-10-14 AU AU2022368858A patent/AU2022368858A1/en active Pending
- 2022-10-14 CN CN202280084050.5A patent/CN118556058A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240415832A1 (en) | 2024-12-19 |
| JP2024539106A (ja) | 2024-10-28 |
| EP4419523A1 (en) | 2024-08-28 |
| CN118556058A (zh) | 2024-08-27 |
| KR20240089771A (ko) | 2024-06-20 |
| MX2024004725A (es) | 2024-05-10 |
| AU2022368858A1 (en) | 2024-05-02 |
| IL312165A (en) | 2024-06-01 |
| EP4419523A4 (en) | 2025-09-17 |
| WO2023069880A1 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240415832A1 (en) | Novel methods | |
| AU2018307480B2 (en) | Organic compounds | |
| WO2021257420A1 (en) | 5-oxopyrrolidine-3-carboxamides as nav1.8 inhibitors | |
| AU2020254812B2 (en) | Methods of treating neuropathic pain | |
| BR112020001666A2 (pt) | compostos orgânicos | |
| US7164021B2 (en) | Opiate analogs selective for the δ-opioid receptor | |
| US20250320214A1 (en) | Organic compounds | |
| EP3914235A2 (en) | Methods of treating addiction | |
| AU2008287445A2 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
| US20250101029A1 (en) | Organic compounds | |
| ES2307025T3 (es) | Combinacion de opioides y un derivado de la piperazina para el tratamiento del dolor. | |
| HK40111276A (zh) | 新方法 | |
| CN114656473B (zh) | 吡咯并嘧啶类化合物、异构体或盐及其制备方法和用途 | |
| WO2026011138A1 (en) | Organic compounds | |
| BR112020001654B1 (pt) | Compostos orgânicos agonistas ou antagonistas de receptores 5- ht2, composição farmacêutica que compreende os ditos compostos e uso dos mesmos para o tratamento ou profilaxia de distúrbios do sistema nervoso central | |
| AU2013205446A1 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240919 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240919 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240919 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20241128 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20250106 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20250825 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20250825 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250825 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260311 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260311 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260311 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260311 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260311 |